Erythropoietin, erythropoiesis and beyond

Chateauvieux, Sébastien; Grigorakaki, Christine; Morceau, Franck; Dicato, Mario; Diederich, Marc

doi:10.1016/j.bcp.2011.06.045

Cited by 152 publications

(135 citation statements)

References 181 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, tissue-protective and antiinflammatory effects have been described in several tissues. Among other functions, EPO elicits neuroprotection after vascular insult, cardioprotection after myocardial infarction, and renoprotection after kidney injury (Figure 1) (Prunier et al 2007;Arcasoy 2010;Chateauvieux et al 2011).…”

Section: Pleiotropic Effects Of Epomentioning

confidence: 99%

The effect of erythropoietin on bone

Rölfing¹

2014

Acta Orthopaedica

View full text Add to dashboard Cite

Section: Pleiotropic Effects Of Epomentioning

confidence: 99%

The effect of erythropoietin on bone

Rölfing¹

2014

Acta Orthopaedica

View full text Add to dashboard Cite

“…Kidney cells are the major producer of EPO in adults and the secreted protein will travel through the blood stream to reach to the bone marrow to stimulate hematopoietic stem cell differentiation to RBC. 1 However, ample studies have evinced the presence of EPO protein and its receptors in extra-hematopoietic tissues including the retina tissue. 2,3 In adults, there is a wide distribution of EPO and EPO receptors (EPOR) reported on the human retinal tissue [4][5][6][7] and retinal pigment epithelium (RPE) 4 (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

show abstract

“…Several growth factors have been identified to regulate regeneration and repair (9,10). Erythropoietin was first characterized as a hematopoietic factor, and it has been used clinically for the treatment of anemia (10)(11)(12). Erythropoietin is a cytokine that is produced primarily in the kidneys by renal cortical fibroblasts (10,11), and which regulates the differentiation and proliferation of erythroid progenitor cells.…”

Section: Introductionmentioning

confidence: 99%

“…Erythropoietin is a cytokine that is produced primarily in the kidneys by renal cortical fibroblasts (10,11), and which regulates the differentiation and proliferation of erythroid progenitor cells. However, due to in-vitro human recombinant erythropoietin stimulates endothelial cell proliferation (10)(11)(12) and angiogenesis (10,13,14), erythropoietin effects may not be limited to bone marrow cells. Moreover, it has been shown to exert pleiotropic properties, such as cytoprotection, anti-inflammation and antiapoptosis, in the central nervous, kidney and liver (12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin ameliorates genetamicin-induced renal toxicity: A biochemical and histopathological study

et al. 2012

View full text Add to dashboard Cite

Background:Investigations have attempted to modify the outcome of tubular injury by either ameliorating renal tubular damage or promoting tubular regeneration in the case of acute tubular necrosis. Objectives: We investigated the protective effect of Eprex an erythropoietin analogue on tubular injury induced by gentamicin (GM). Materials and Methods: Forty male Wistar rats were randomly divided into four groups. In group 1,rats were served as a sham group. In group 2, rats were injected intraperitoneally with 100 mg/kg of GM for 10 consecutive days (positive control group) and then were sacrificed. In group 3, rats received GM for 10 days then Eprex 100U/kg was injected intraperitoneally for the next 10 days and then they were sacrificed at the day 20th. In group 4 rats were injected a combination of GM (80 mg/kg) and Eprex 100U/kg intraperitoneally for 10 days and then were sacrificed. Results: The results indicated that, Eprex prevented the increase in serum creatinine (Cr) and blood urea nitrogen (BUN). The effect of Eprex on damage score, showed that co-administration of GM and Eprex (group 3 and 4) reduced the kidney tissue damage compared to positive control group (P<0.05). This result indicat that Eprex potentially can reduce or prevent the kidney tissue damage. Conclusions: Ameliorative effect of Eprex when the drug was given in combination with GM and also when the drug was applied after GM-induced tubular damage, revealed the renoprotective potency of Eprex. Eprex is a promising drug to prevent or attenuate tubular damage induced by GM or other nephrotoxic agents which act through the same mechanisms as gentamicin.

show abstract

Erythropoietin, erythropoiesis and beyond

Cited by 152 publications

References 181 publications

The effect of erythropoietin on bone

The effect of erythropoietin on bone

Revisiting the role of erythropoietin for treatment of ocular disorders

Erythropoietin ameliorates genetamicin-induced renal toxicity: A biochemical and histopathological study

Contact Info

Product

Resources

About